Abdalla Berun A, Abdullah Hiwa O, Nasralla Hawkar A, Ali Rebaz M, Omar Sami S, Ghafour Abdullah K, Asaad Saywan K, Raoof Soran S, Tahir Soran H, Rashid Rezheen J, Mohammed Ayoob A, Sabr Nasren Sharef, Hasan Ali H, Mustafa Lawen Jamal, Salih Ameer M, Kakamad Fahmi H
Scientific Affairs Department, Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Iraq.
Kscien Organization for Scientific Research (Middle East Office), Hamid Street, Azadi mall, Sulaymaniyah, Iraq.
Case Reports Plast Surg Hand Surg. 2025 May 10;12(1):2503195. doi: 10.1080/23320885.2025.2503195. eCollection 2025.
Microwave ablation (MWA) utilizes electromagnetic methods to destroy tumors, employing devices operating at 900 MHz or above frequencies. MWA has emerged as a recent alternative for treating osteoid osteoma (OO), providing similar accessibility, safety, and technical effectiveness as radiofrequency ablation. This systematic review aims to evaluate the safety and efficacy of MWA in treating OO.
A systematic review of published studies on the use of MWA in managing OO was conducted. Studies were excluded if they were 1) not written in English, 2) case reports, 3) lacked adequate peer review, or 4) consisted solely of abstracts. Before full-text assessment, titles, and abstracts were screened. Extracted data included author, year, study design, patient count, age, gender, OO site, ablation power (watts), duration, complications, outcome, and recurrence. The data were analyzed and presented as means, frequencies, and percentages.
Eight studies, including 143 cases, met the inclusion criteria; among these cases, 59.44% were male, and the mean age was 19.03 ± 7.09. Most of the OOs were in the femur, 54.54%. MWA at 60 W was the prevailing power setting, utilized in 37 cases (25.87%), with an ablation time of 90 s for 95 cases (66.43%). Clinical success was achieved in 137 (95.80%) cases, with recurrence observed in 4 cases (2.80%). However, 16 minor and major complications were observed despite the overall success.
Percutaneous MWA may represent an efficient choice for the minimally invasive management of OO, demonstrating a minimal risk of complications and recurrence.
微波消融（MWA）利用电磁方法破坏肿瘤，采用工作频率在900兆赫兹或以上的设备。微波消融已成为治疗骨样骨瘤（OO）的一种新选择，在可及性、安全性和技术有效性方面与射频消融相似。本系统评价旨在评估微波消融治疗骨样骨瘤的安全性和有效性。
对已发表的关于微波消融治疗骨样骨瘤的研究进行系统评价。如果研究存在以下情况则被排除：1）非英文撰写；2）病例报告；3）缺乏充分的同行评审；4）仅包含摘要。在进行全文评估之前，先对标题和摘要进行筛选。提取的数据包括作者、年份、研究设计、患者数量、年龄、性别、骨样骨瘤部位、消融功率（瓦特）、持续时间、并发症、结果和复发情况。对数据进行分析，并以均值、频率和百分比的形式呈现。
八项研究共143例符合纳入标准；其中男性占59.44%，平均年龄为19.03±7.09岁。大多数骨样骨瘤位于股骨，占54.54%。60瓦是最常用的微波消融功率设置，37例（25.87%）采用此设置，95例（66.43%）的消融时间为90秒。137例（95.80%）临床治疗成功，4例（2.80%）出现复发。然而，尽管总体治疗成功，但仍观察到16例轻微和严重并发症。
经皮微波消融可能是骨样骨瘤微创治疗的有效选择，并发症和复发风险极小。
